[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sangamo Therapeutics Inc (SGMO)

Sangamo Therapeutics Inc (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 47,642
  • Shares Outstanding, K 414,276
  • Annual Sales, $ 39,550 K
  • Annual Income, $ -122,930 K
  • EBIT $ -108 M
  • EBITDA $ -100 M
  • 60-Month Beta 1.04
  • Price/Sales 1.06
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings $-0.07 on 03/30/26
  • Next Earnings Date 05/11/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 1
  • High Estimate $-0.04
  • Low Estimate $-0.04
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) +71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1000 +21.00%
on 05/07/26
0.2950 -58.98%
on 04/16/26
-0.1302 (-51.83%)
since 04/10/26
3-Month
0.1000 +21.00%
on 05/07/26
0.5500 -78.00%
on 02/25/26
-0.2703 (-69.08%)
since 02/11/26
52-Week
0.1000 +21.00%
on 05/07/26
0.7660 -84.20%
on 09/29/25
-0.5792 (-82.72%)
since 05/09/25

Most Recent Stories

More News
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq...

SGMO : 0.1210 (+5.22%)
Sangamo: Q4 Earnings Snapshot

Sangamo: Q4 Earnings Snapshot

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292...

SGMO : 0.1210 (+5.22%)
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has...

SGMO : 0.1210 (+5.22%)

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 0.1435
2nd Resistance Point 0.1363
1st Resistance Point 0.1286
Last Price 0.1210
1st Support Level 0.1137
2nd Support Level 0.1065
3rd Support Level 0.0988

See More

52-Week High 0.7660
Fibonacci 61.8% 0.5116
Fibonacci 50% 0.4330
Fibonacci 38.2% 0.3544
Last Price 0.1210
52-Week Low 0.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.